The COVID-19 virus is not going anywhere any time soon and, as new variants keep cropping up across the globe, vaccine development cannot afford to stand still.
There are currently just over 100 vaccines in clinical development worldwide but only four authorised vaccines in the EU, of which mRNA vaccines dominate.
As the initial vaccine race has started to subside, discussion have started focusing on the need for booster shots and a longer-term vaccination strategy.
How can the EU strengthen its vaccine autonomy? What kind of booster vaccines will be needed? And what will the strategies for coping with COVID look like in the near future?
In this Special Report, EURACTIV looks at what we should expect in this ongoing vaccination marathon.
-
Spanish firm finetunes ‘second generation’ COVID-19 vaccine for EU’s booster campaign
A Spanish company active in animal health stands ready to start clinical trials and get the EU's regulatory go-ahead for a 'deadline-proof' recombinant protein vaccine. EURACTIV spoke with the company's chief of the vaccine programme.
-
Protein subunit and inactivated vaccines line up to join vaccination campaigns
The EU seems to be comfortable with betting on mRNA COVID vaccines for now. But just around the corner, vaccines developed under other platforms are lining up, with recombinant proteins and the whole virion-inactivated vaccines leading the way.